Elevance Health Price Targets Span $320 to $425 Following Analyst Revisions

ELVELV

Cantor Fitzgerald acquired a new 4,510-share stake in Elevance Health during Q3, valued at $1.457 million, contributing to the 89.24% institutional ownership level. Guggenheim raised its price target to $398 while UBS, Barclays and Deutsche Bank lowered theirs to $425, $385 and $320 respectively, leaving a consensus average at $396.21.

1. Cantor Fitzgerald’s Strategic Stake Acquisition

During the third quarter, Cantor Fitzgerald Investment Advisors L.P. initiated a new position in Elevance Health by purchasing 4,510 shares valued at approximately 1.46 million. This move underscores growing institutional conviction in the company’s business model. Alongside Cantor Fitzgerald, at least five other firms—including Vermillion & White Wealth Management, BOK Financial Private Wealth, Glass Jacobson Investment Advisors, Trust Co. of Toledo NA OH, and VSM Wealth Advisory—either expanded or established fresh stakes. Collectively, hedge funds and institutional investors now control more than 89 percent of the outstanding shares, reinforcing Elevance Health’s status as a cornerstone holding in professional portfolios.

2. Robust Third-Quarter Performance Highlights Operational Strength

In its most recent quarterly report, Elevance Health delivered earnings per share of 6.03, surpassing consensus estimates by a full dollar and demonstrating year-over-year revenue growth of 12 percent to 50.09 billion. The company’s net margin held at 2.84 percent, while return on equity reached 16.17 percent, reflecting disciplined cost management and effective care coordination. Managed-care membership expanded across core segments, and medical loss ratios improved sequentially, signaling sustained profitability trends. On average, analysts now forecast nearly 34 dollars in earnings per share for the full year, underpinning expectations of continuing cash flow generation.

3. Consensus Ratings and Shareholder Returns

Analyst coverage remains balanced, with a consensus rating of Hold derived from 12 Buy opinions, 11 Holds and a single Sell. The average price objective sits near 396.21, implying modest upside potential. Recent rating activity includes a downward adjustment by UBS and Barclays, while Guggenheim raised its outlook following strong quarterly delivery. Elevance Health’s quarterly dividend of 1.71, representing a yield of approximately 2 percent and a payout ratio under 28 percent, was paid in mid-December. The company maintains a conservative leverage profile, with a debt-to-equity ratio below unity and liquidity metrics comfortably above one, supporting its ability to sustain distributions and fund ongoing strategic investments.

Sources

ID